{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T03:41:50Z","timestamp":1783222910607,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Diabetes mellitus-related cardiomyopathy (DMCMP), defined as left ventricular (LV) dysfunction caused by hyperglycemia in the absence of coronary artery disease, leads to heart failure (HF). Previous studies have shown that treatment with sodium-glucose co-transporter 2 inhibitor (SGLT2i) reduces the risk of exacerbation of HF. The beneficial effects of SGLT2i on HF depend not only on indirect actions such as osmotic diuresis but also on direct actions on the myocardium, leading to improvements in LV function. However, it remains unclear whether SGLT2i treatment is equally effective in any phase of DMCMP. The aim of this observational study was to compare the efficacy of SGLT2i treatment on LV dysfunction between early and advanced DMCMP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty-five symptomatic non-ischemic HF patients with LV ejection fraction\u2009&gt;\u200940% and type 2 diabetes mellitus (T2DM) treated with empagliflozin (EMPA group) and 20 controls treated without SGLT2i were enrolled. According to the myocardial extracellular volume fraction (ECV), a reliable marker of cardiac fibrosis quantified by cardiac magnetic resonance, the EMPA group was further divided into early DMCMP (n\u2009=\u200916, ECV\u2009\u2264\u200930%) and advanced DMCMP (n\u2009=\u200919, ECV\u2009&gt;\u200930%) groups and followed up prospectively. Echocardiography was performed at baseline and after 12\u00a0months. LV function assessed as LV global longitudinal strain (LVGLS) and the ratio of early diastolic mitral inflow velocity to early diastolic mitral annular velocity (E\/e\u2032) were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ECV was strongly correlated with T2DM duration (r<jats:sup>2<\/jats:sup>\u2009=\u20090.65, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). At baseline, each group had a similar background. After 12\u00a0months, the EMPA group, especially the early DMCMP group, showed remarkable improvements in LVGLS (\u0394LVGLS: 2.9\u2009\u00b1\u20093.0% (EMPA) vs. 0.6\u2009\u00b1\u20092.2% (controls), <jats:italic>p<\/jats:italic>\u2009=\u20090.005, and 4.6\u2009\u00b1\u20091.5% (early DMCMP) vs. 1.6\u2009\u00b1\u20093.3% (advanced DMCMP), <jats:italic>p<\/jats:italic>\u2009=\u20090.003) and E\/e\u2032 (\u0394E\/e\u2032:\u2009\u2212\u20091.5\u2009\u00b1\u20094.7 vs.\u2009\u2212\u20090.3\u2009\u00b1\u20093.0, <jats:italic>p<\/jats:italic>\u2009=\u20090.253, and\u2009\u2212\u20093.4\u2009\u00b1\u20095.5 vs.\u2009\u2212\u20090.1\u2009\u00b1\u20093.5, <jats:italic>p<\/jats:italic>\u2009=\u20090.043).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The positive effects of empagliflozin on LV dysfunction were more remarkable in early than in advanced DMCMP. Early intervention of SGLT2i for DMCMP may be preferable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-02024-3","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T19:02:39Z","timestamp":1619722959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-1421","authenticated-orcid":false,"given":"Satoshi","family":"Oka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuomi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"issue":"19","key":"2024_CR1","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","volume":"241","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035\u20138.","journal-title":"JAMA"},{"issue":"25","key":"2024_CR2","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","volume":"115","author":"S Boudina","year":"2007","unstructured":"Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213\u201323.","journal-title":"Circulation"},{"key":"2024_CR3","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","volume":"36","author":"MS Petar","year":"2015","unstructured":"Petar MS, Walter JP. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive or dilated phenolypes. Eur Heart J. 2015;36:1718\u201327.","journal-title":"Eur Heart J"},{"issue":"5","key":"2024_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.echo.2014.01.001","volume":"27","author":"L Ernande","year":"2014","unstructured":"Ernande L, Bergerot C, Girerd N, Thibault H, Davidsen ES, Pignon-Blanc PG, et al. Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus. J Am Soc Echocardiogr. 2014;27(5):479\u201388.","journal-title":"J Am Soc Echocardiogr"},{"key":"2024_CR5","first-page":"151","volume":"6","author":"V Chavali","year":"2013","unstructured":"Chavali V, Tyagi SC, Mishra PK. Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes. 2013;6:151\u201360.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"22","key":"2024_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"2024_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"2024_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. DECLARE-TIMI 58 Investigators. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"2024_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"2024_CR10","doi-asserted-by":"publisher","first-page":"141324","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):141324.","journal-title":"N Engl J Med."},{"key":"2024_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17:132\u20139.","journal-title":"Cardiovasc Diabetol"},{"key":"2024_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-019-0985-z","volume":"19","author":"H Tanaka","year":"2020","unstructured":"Tanaka H, Soga F, Tatsumi K, Mochizuki Y, Sano H, Toki H, et al. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Cardiovasc Diabetol. 2020;19:6\u201314.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"2024_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","volume":"2","author":"M Packer","year":"2017","unstructured":"Packer M, Anker SD, Butler J, Fillippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025\u20139.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"2024_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","volume":"15","author":"KG Alberti","year":"1998","unstructured":"Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539\u201353.","journal-title":"Diabet Med"},{"issue":"12","key":"2024_CR15","doi-asserted-by":"publisher","first-page":"e009535","DOI":"10.1161\/CIRCIMAGING.119.009535","volume":"12","author":"EY Yang","year":"2019","unstructured":"Yang EY, Ghosn MG, Khan MA, Gramze NL, Brunner G, Nabi F, et al. Myocardial extracellular volume fraction adds prognostic information beyond myocardial replacement fibrosis. Circ Cardiovasc Imaging. 2019;12(12):e009535.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"2024_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/eht193","volume":"35","author":"TC Wong","year":"2014","unstructured":"Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Euro Heart J. 2014;35(10):657\u201364.","journal-title":"Euro Heart J"},{"issue":"5","key":"2024_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/jdi.12181","volume":"5","author":"M Iwata","year":"2014","unstructured":"Iwata M, Matsushita Y, Fukuda K, Wakura T, Okabe K, Koshimizu Y, et al. Secretory units of islets in transplantation index is a useful predictor of insulin requirement in Japanese type 2 diabetic patients. J Diabetes Investig. 2014;5(5):570\u201380.","journal-title":"J Diabetes Investig"},{"issue":"7","key":"2024_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2008.04.047","volume":"52","author":"I Olivotto","year":"2008","unstructured":"Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(7):559\u201366.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2024_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233\u201370.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mrm.20110","volume":"52","author":"DR Messroghli","year":"2004","unstructured":"Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified look-locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52:141\u20136.","journal-title":"Magn Reson Med"},{"issue":"1","key":"2024_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12933-017-0651-2","volume":"17","author":"Y Cao","year":"2018","unstructured":"Cao Y, Zeng W, Cui Y, Kong X, Wang M, Yu J, et al. Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain. Cardiovasc Diabetol. 2018;17(1):7\u201318.","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"2024_CR22","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1161\/CIRCULATIONAHA.110.968057","volume":"122","author":"M Kohlhaas","year":"2010","unstructured":"Kohlhaas M, Maack C. Adverse bioenergetic consequences of Na+-Ca2+ exchanger-mediated Ca2+ influx in cardiac myocytes. Circulation. 2010;122(22):2273\u201380.","journal-title":"Circulation"},{"issue":"3","key":"2024_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, Wust RC, Fiolet Jan WT, Stienen Ger JM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na + through inhibition of the cardiac Na +\/H + exchanger in rats and rabbits. Diabetologia. 2017;60(3):568\u201373.","journal-title":"Diabetologia"},{"key":"2024_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","volume":"13","author":"B Lin","year":"2014","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148\u201362.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2024_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9\u201323.","journal-title":"Cardiovasc Diabetol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02024-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02024-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02024-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T19:09:43Z","timestamp":1619723383000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02024-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2024"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02024-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the Fujieda Municipal General Hospital. All participants provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The consent to publish was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}